Tom 14, Nr 2 (2017)
Nadciśnienie tętnicze
Opublikowany online: 2017-08-24

dostęp otwarty

Wyświetlenia strony 348
Wyświetlenia/pobrania artykułu 611
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Komentarz

Krzysztof Narkiewicz1
Choroby Serca i Naczyń 2017;14(2):64-65.

Streszczenie

Brak

Referencje

  1. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016; 388(10060): 2665–2712.
  2. Christensen A, Christrup LL, Fabricius PE, et al. The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. J Hypertens. 2010; 28(1): 194–200.
  3. Chrostowska M, Narkiewicz K. Improving patient compliance with hypertension treatment: mission possible? Curr Vasc Pharmacol. 2010; 8(6): 804–807.
  4. Mancia G, Parodi A, Merlino L, et al. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens. 2011; 29(5): 1012–1018.
  5. Kita T, Sakima A, Yokota N, et al. Differences in 24-h blood pressure profile of Japanese hypertensive patients under ARB treatment. Clin Exp Hypertens. 2015; 37(7): 574–579.
  6. Shimizu M, Hoshide S, Ishikawa J, et al. Correlation of central blood pressure to hypertensive target organ damages during antihypertensive treatment: the J-TOP Study. Am J Hypertens. 2015; 28(8): 980–986.
  7. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289(1): 65–69.
  8. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012; 39(2 Suppl 2): S1–S59.
  9. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374(21): 2009–2020.
  10. Yusuf S, Lonn E, Pais P, et al. HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016; 374(21): 2032–2043.